Clinical trial · Observational
Clinical Tumor Anemia Registry (TAR)
Clinical Registry Describing Treatment Reality of Patients With Cancer-(Therapy)-Induced Anemia
NCT01795690CI-TRIAL-00021167TARcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Documentation of therapies
- timeFrame
- 12 weeks per patient
- description
- Overview on the current routine treatment of anemia in cancer patients in Germany
Secondary outcomes (1)
- measure
- Change in hemoglobin levels and QoL
- timeFrame
- 12 weeks per patient
- description
- Effectiveness of different antianemic treatments is investigated by measuring increase of hemoglobin levels and QoL (FACT-An and FACT-GP). Baseline in hemoglobin (before treatment) is compared with hemoglobin levels after treatment. Each patient is followed for a maximum of 12 weeks to obtain data about the course of the treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed malignant disease * Hemoglobin level \< 11 g/dl (female) or \< 12 g/dl (male) * Start of antianemic therapy no more than 7 days prior to informed consent * Performance status 0 - 3 (Karnofsky-Index \>= 40%) * Minimum age: 18 years * Informed written consent Exclusion Criteria: * Hypersensitivity against antianemic therapies * Myelodysplastic Syndrome * Experimental antianemic therapy
References
Publications (1)
- RESULTSteinmetz T, Schroder J, Plath M, Link H, Vogt M, Frank M, Marschner N. Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study-The Tumor Anemia Registry. Anemia. 2016;2016:8057650. doi: 10.1155/2016/8057650. Epub 2016 Feb 4. PMID 26966573